Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.

<h4>Introduction</h4>To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in prostate cancer patients with high- or very high-risk prostate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, Ick Joon Cho, Yong-Hyub Kim, Shin Haeng Cho, Seung Il Jung, Taek Won Kang, Dong Deuk Kwon
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d1086883b18a4175bd940956767abff3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1086883b18a4175bd940956767abff3
record_format	dspace
spelling	oai:doaj.org-article:d1086883b18a4175bd940956767abff32021-12-02T20:15:50ZFavorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.1932-620310.1371/journal.pone.0248461https://doaj.org/article/d1086883b18a4175bd940956767abff32021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0248461https://doaj.org/toc/1932-6203<h4>Introduction</h4>To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in prostate cancer patients with high- or very high-risk prostate cancer who underwent radiotherapy (RT).<h4>Materials and methods</h4>A total of 197 patients with prostate cancer received RT, with a follow-up of ≥12 months. Biochemical failure was defined as PSA ≥nadir + 2 ng/mL after RT. We analyzed clinical outcomes, including survival, failure patterns, and prognostic factors affecting outcomes.<h4>Results</h4>Biochemical failure-free survival (BCFFS), clinical failure-free survival, distant metastasis-free survival, cancer-specific survival, and overall survival (OS) rates at 5 years were 91.1%, 95.4%, 96.9%, 99.5%, and 89.1%, respectively. Administration of long-term A-ADT significantly predicted favorable BCFFS (p = 0.027) and OS (p < 0.001) in multivariate analysis. Nadir PSA ≤0.001 ng/mL was an independent prognostic factor for BCFFS (p = 0.006) and OS (p = 0.021). The use of long-term A-ADT significantly affected nadir PSA ≤0.001 ng/mL (p < 0.001). The patients with A-ADT for 1 year or longer had better BCFFS or OS than those for less than 1 year or those without A-ADT (p < 0.001). The best prognosis was demonstrated in patients treated with long-term A-ADT and nadir PSA ≤0.001 ng/mL in BCFFS (p < 0.001).<h4>Conclusion</h4>The addition of long-term A-ADT over 1 year to RT demonstrated good treatment outcomes in patients with locally advanced prostate cancer. Achieving a nadir PSA value ≤0.001 ng/mL using combination therapy with RT and A-ADT is a powerful clinical predictor of treatment outcomes.Jae-Uk JeongTaek-Keun NamJu-Young SongMee Sun YoonSung-Ja AhnWoong-Ki ChungIck Joon ChoYong-Hyub KimShin Haeng ChoSeung Il JungTaek Won KangDong Deuk KwonPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 3, p e0248461 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jae-Uk Jeong Taek-Keun Nam Ju-Young Song Mee Sun Yoon Sung-Ja Ahn Woong-Ki Chung Ick Joon Cho Yong-Hyub Kim Shin Haeng Cho Seung Il Jung Taek Won Kang Dong Deuk Kwon Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
description	<h4>Introduction</h4>To determine the prognostic significance of long-term adjuvant androgen deprivation therapy (A-ADT) over 1 year in achieving undetectable levels of prostate-specific antigen (PSA) less than 0.001 ng/mL in prostate cancer patients with high- or very high-risk prostate cancer who underwent radiotherapy (RT).<h4>Materials and methods</h4>A total of 197 patients with prostate cancer received RT, with a follow-up of ≥12 months. Biochemical failure was defined as PSA ≥nadir + 2 ng/mL after RT. We analyzed clinical outcomes, including survival, failure patterns, and prognostic factors affecting outcomes.<h4>Results</h4>Biochemical failure-free survival (BCFFS), clinical failure-free survival, distant metastasis-free survival, cancer-specific survival, and overall survival (OS) rates at 5 years were 91.1%, 95.4%, 96.9%, 99.5%, and 89.1%, respectively. Administration of long-term A-ADT significantly predicted favorable BCFFS (p = 0.027) and OS (p < 0.001) in multivariate analysis. Nadir PSA ≤0.001 ng/mL was an independent prognostic factor for BCFFS (p = 0.006) and OS (p = 0.021). The use of long-term A-ADT significantly affected nadir PSA ≤0.001 ng/mL (p < 0.001). The patients with A-ADT for 1 year or longer had better BCFFS or OS than those for less than 1 year or those without A-ADT (p < 0.001). The best prognosis was demonstrated in patients treated with long-term A-ADT and nadir PSA ≤0.001 ng/mL in BCFFS (p < 0.001).<h4>Conclusion</h4>The addition of long-term A-ADT over 1 year to RT demonstrated good treatment outcomes in patients with locally advanced prostate cancer. Achieving a nadir PSA value ≤0.001 ng/mL using combination therapy with RT and A-ADT is a powerful clinical predictor of treatment outcomes.
format	article
author	Jae-Uk Jeong Taek-Keun Nam Ju-Young Song Mee Sun Yoon Sung-Ja Ahn Woong-Ki Chung Ick Joon Cho Yong-Hyub Kim Shin Haeng Cho Seung Il Jung Taek Won Kang Dong Deuk Kwon
author_facet	Jae-Uk Jeong Taek-Keun Nam Ju-Young Song Mee Sun Yoon Sung-Ja Ahn Woong-Ki Chung Ick Joon Cho Yong-Hyub Kim Shin Haeng Cho Seung Il Jung Taek Won Kang Dong Deuk Kwon
author_sort	Jae-Uk Jeong
title	Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
title_short	Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
title_full	Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
title_fullStr	Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
title_full_unstemmed	Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
title_sort	favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/d1086883b18a4175bd940956767abff3
work_keys_str_mv	AT jaeukjeong favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT taekkeunnam favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT juyoungsong favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT meesunyoon favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT sungjaahn favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT woongkichung favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT ickjooncho favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT yonghyubkim favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT shinhaengcho favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT seungiljung favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT taekwonkang favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer AT dongdeukkwon favorableprognosisofpatientswhoreceivedadjuvantandrogendeprivationtherapyafterradiotherapyachievingundetectablelevelsofprostatespecificantigeninhighorveryhighriskprostatecancer
_version_	1718374553188564992

Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.

Ejemplares similares